肝“体阴而用阳”、“阳常有余阴常不足”，故“体阴而阴不足”是肝病的基础矛盾，研究证实育阴软肝颗粒（YRD）对肝纤维化（HF）有确切疗效，但具体机制不清；肝阴不足和HF与cAMP/PKA/CREB信号通路偏亢有关，而TGF-β1/Smads/CTGF信号通路异常激活在HF过程中发挥关键作用。据此，我们提出“‘体阴而阴不足’是肝病的基础矛盾，肝阴不足是肝纤维化的基础病机，而血瘀癥积是肝纤维化的典型症状，育阴软肝颗粒通过调节cAMP/PKA/CREB信号通路而育阴软肝，通过调节TGF-β1/Smads/CTGF信号通路而化瘀消癥”的工作假说。在复制HF模型的基础上，研究YRD缓解阴虚表征、抗HF过程中对上述信号通路的调控。本课题首次提出肝阴不足是HF的基础病机，并探讨上述信号通路在YRD治疗HF过程中的作用及相互关系，为临床防治HF提供新思路与新方法。

Based on body Yin but deficiency and therapy of raising Yin and soften hepar, Yuyin Ruangan Granule (YRD) has exact treatment on hepatic fibrosis(HF). Hepatic Yin deficiency and hepatic fibrosis are related to cAMP/PKA/CREB signal pathway, and abnormal activation of TGF-β1/Smads/CTGF plays an important role. Based on above, we propose the hypothesis that deficiency of hepatic yin is the basic pathogenesis of HF and treating mechanism of YRD may be related to the signaling pathways of cAMP/PKA/CREB and TGF-β1/Smads/CTGF. We study YRD’s effectiveness on characterization of Yin deficiency and signaling pathways after replicating model of HF. In this project, we first put forward the basic pathogenesis of HF, which is deficiency of hepatic yin, and discuss the effects of YRD on cAMP/PKA/CREB and TGF-β1/Smads/CTGF in treating HF from organ, cell and molecule. This topic provides a new idea and method for treatment of the HF.